Dharmarajan Subramanian, Gurel Zafer, Wang Shoujian, Sorenson Christine M, Sheibani Nader, Belecky-Adams Teri L
Department of Biology, Indiana University-Purdue University Indianapolis,, Indianapolis, IN ; Center for Regenerative Biology and Medicine, Indiana University- Purdue University Indianapolis, Indianapolis, IN.
Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Mol Vis. 2014 Jul 31;20:1085-108. eCollection 2014.
The focus of this study was to determine whether bone morphogenetic proteins (BMPs) trigger reactive gliosis in retinal astrocytes and/or Müller glial cells.
Retinal astrocytes and the Müller glial cell line MIO-M1 were treated with vehicle, BMP7, or BMP4. Samples from the treated cells were analyzed for changes in gliosis markers using reverse transcriptase - quantitative PCR (RT-qPCR) and western blotting. To determine potential similarities and differences in gliosis states, control and BMP-treated cells were compared to cells treated with sodium peroxynitrite (a strong oxidizing agent that will bring about some aspects of gliosis). Last, mature mice were microinjected intravitreally with BMP7 and analyzed for changes in gliosis markers using RT-qPCR, western blotting, and immunohistochemistry.
Treatment of retinal astrocyte cells and Müller glial cells with BMP7 regulated various reactive gliosis markers. When compared to the response of cells treated with sodium peroxynitrite, the profiles of gliosis markers regulated due to exposure to BMP7 were similar. However, as expected, the profiles including the oxidative agent and growth factor were not identical. Treatment of cells with BMP4, however, showed an attenuated response in comparison to peroxynitrite and BMP7 treatment. Injection of BMP7 into the mouse retina also triggered a reactive gliosis response 7 days after injection.
BMP7 induced changes in levels of mRNA and protein markers typically associated with reactive gliosis in retinal astrocytes and Müller glial cells, including glial fibrillary acidic protein (GFAP), glutamine synthetase (GS), a subset of chondroitin sulfate proteoglycans (CSPGs), matrix metalloproteinases (MMPs), and other molecules.
本研究的重点是确定骨形态发生蛋白(BMPs)是否会引发视网膜星形胶质细胞和/或米勒胶质细胞的反应性胶质增生。
用溶剂、BMP7或BMP4处理视网膜星形胶质细胞和米勒胶质细胞系MIO-M1。使用逆转录定量PCR(RT-qPCR)和蛋白质印迹法分析处理后细胞样本中胶质增生标志物的变化。为了确定胶质增生状态的潜在异同,将对照细胞和经BMP处理的细胞与用过氧亚硝酸钠处理的细胞(一种会引发某些胶质增生方面变化的强氧化剂)进行比较。最后,向成年小鼠玻璃体内微量注射BMP7,并使用RT-qPCR、蛋白质印迹法和免疫组织化学分析胶质增生标志物的变化。
用BMP7处理视网膜星形胶质细胞和米勒胶质细胞可调节多种反应性胶质增生标志物。与用过氧亚硝酸钠处理的细胞的反应相比,因接触BMP7而调节的胶质增生标志物谱相似。然而,正如预期的那样,包括氧化剂和生长因子在内的谱并不相同。然而,与过氧亚硝酸钠和BMP7处理相比,用BMP4处理细胞显示出减弱的反应。向小鼠视网膜注射BMP7在注射后7天也引发了反应性胶质增生反应。
BMP7诱导视网膜星形胶质细胞和米勒胶质细胞中通常与反应性胶质增生相关的mRNA和蛋白质标志物水平发生变化,包括胶质纤维酸性蛋白(GFAP)、谷氨酰胺合成酶(GS)、硫酸软骨素蛋白聚糖(CSPGs)的一个子集、基质金属蛋白酶(MMPs)和其他分子。